Shares of Novo Nordisk (NVO) trading in New York are down $8.93, or 13%, to $60.07 in the pre-market session after the company lowered its sales and operating profit outlook for 2025, citing lower growth expectations for Wegovy in the U.S. obesity market, lower growth expectations for Ozempic in the U.S. GLP-1 diabetes market, as well as lower-than-expected penetration for Wegovy in select IO markets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk lowers sales and operating profit outlook for 2025
- Lawmakers urge FDA to crack down on knockoff weight loss drugs, Bloomberg says
- Novo Nordisk’s Stock Soars Amid Strategic Moves
- HIMS Lawsuit Alert! Hims & Hers Faces Class Action Lawsuit After Wegovy Scandal
- Avidity, Phathom mentioned as potential takeout targets at Needham